http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013544887-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013544887-A |
| titleOfInvention | Use of laquinimod to reduce fatigue, improve functional status and improve quality of life in patients with multiple sclerosis |
| abstract | The present invention relates to reducing or suppressing the progression of the level of fatigue in a human patient with multiple sclerosis, to improve or suppress the deterioration of the functional state of a human patient with multiple sclerosis, and to a human with multiple sclerosis. Provided is a method for improving or suppressing a deterioration in the overall health of a patient, comprising orally administering laquinimod or a pharmaceutically acceptable salt thereof to a human patient. The present invention also provides a method for providing neuroprotection to a human subject, comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof. [Selection] Figure 1 |
| priorityDate | 2010-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 246.